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Cyclooxygenase-2 (COX-2) is overexpressed in lung cancer, especially in adenocarcinoma (ADC). Our aim was to determine the
prognostic value of COX-2 on survival in patients with lung cancer. Studies evaluating the survival impact of COX-2 in lung cancer,
published until December 2005, were selected. Data for estimation of individual hazard ratios (HR) for survival were extracted from
the publications and combined in a pooled HR. Among 14 eligible papers, all dealing with non-small-cell lung cancer, 10 provided
results for meta-analysis of survival data (evaluable studies). Cyclooxygenase-2 positivity was associated with reduced survival,
improved survival or no statistically significant impact in six, one and seven studies, respectively. Combined HR for the 10 evaluable
studies (1236 patients) was 1.39 (95% confidence intervals (CI): 0.97–1.99). In stage I lung cancer (six evaluable studies, 554
patients), it was 1.64 (95% CI: 1.21–2.24). No significant impact was shown in ADC. A slight detrimental effect on survival in patients
with lung cancer is associated with COX-2 expression, but the statistical significance is not reached. This effect is statistically significant
in stage I, suggesting that COX-2 expression could be useful at early stages to distinguish those with a worse prognosis.
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Lung cancer is a major cause of death despite diagnostic and
therapeutic improvements. The overall 5-year survival rate is
around 10% (Boyle and Ferlay, 2005). Some independent
prognostic factors for survival have already been identified. They
include, for small cell lung cancer (SCLC): disease extent and
performance status (PS) (Paesmans et al, 2000); for non-small-cell
lung cancer (NSCLC): PS, stage and, with lower impact, age, sex
and weight loss (Paesmans et al, 1995; Strauss, 1997). The
biological factors involved in carcinogenesis should also be
considered as potential survival prognostic factors. Some of them,
like angiogenesis and factors reflecting proliferative state, have
already been identified in patients with lung cancer (Kanters et al,
1995). In order to clarify the prognostic impact of other biological
factors in lung cancer, our group has performed systematic reviews
of the literature with meta-analyses. It allowed us to show that
VEGF (Delmotte et al, 2002), microvessel density (Meert et al,
2002b), EGFR (Meert et al, 2002a), HER-2/Neu (Meert et al, 2003),
Ki-67 (Martin et al, 2004), K-Ras (Mascaux et al, 2005a) and p53
(Steels et al, 2001) have a negative impact on survival, whereas
Bcl-2 (Martin et al, 2003) is associated with a favourable survival
effect, at least when studying their impact in univariate analysis.
Recent attention has been drawn to prostaglandins and
cyclooxygenases (COX) with the discovery that colonic polyps in
patients with familial adenomatous polyposis (FAP) are decreased
after the administration of non-steroidal anti-inflammatory drugs
(NSAIDs) (Waddell and Loughry, 1983). Cyclooxygenases are key
enzymes in the conversion of arachidonic acid to prostaglandin
and exist as two isoforms, COX-1 and COX-2 (Smith and
Langenbach, 2001). Cyclooxygenase-1 is constitutively expressed
in nearly all cell types and plays a central role in many normal
physiological processes, such as cytoprotection of gastric mucosa.
COX-2 is a highly inducible gene, activated by cytokines, growth
factors, phorbol esters, oncogenes and chemical carcinogens
(Smith and Langenbach, 2001). Overexpression of COX-2 has
been reported in many human malignancies including head and
neck carcinomas (Gallo et al, 2002; Lin et al, 2002), oesophagus
(Lagorce et al, 2003), colon (Sinicrope and Gill, 2004), breast
(Ranger et al, 2004), pancreas (Kokawa et al, 2001) and prostatic
cancer (Edwards et al, 2004).
In NSCLC, an increase in COX-2 expression was detected both in
adenocarcinomas (ADC) and in squamous cell carcinomas
(SQCC), but at a higher level in ADC than in SQCC (Hida et al,
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s1998; Wolff et al, 1998; Ochiai et al, 1999). Cyclooxygenase-2
expression was also increased in atypical adenomatous hyper-
plasia, a possible precursor of ADC (Hida et al, 1998; Wolff et al, 1998;
Hosomi et al, 2000; Hasturk et al, 2002) and in severe dysplasia
and in situ carcinoma, precursors of SQCC (Mascaux et al, 2005b).
However, the literature remains controversial about the prognostic
value of COX-2 for survival in patients with lung cancer. In order
to clarify this question, we performed a systematic review of the
literature with methodological assessment and meta-analysis.
MATERIALS AND METHODS
Selection of the publications
To be eligible for the systematic review, a study had to fulfil the
following criteria: to deal only with lung cancer (any stage or
histology), to analyse the association between COX-2 and survival,
to assess COX-2 on the primary tumour (not on metastatic tissue
or tissue adjacent to the tumour), to have been published as a full
paper in English or French. Abstracts were excluded because they
do not provide sufficient data to evaluate the methodology of the
trial and/or to perform meta-analysis.
Studies were identified by an electronic search on Medline
databank and using the following keywords: ‘lung cancer’, ‘lung
carcinoma’, ‘lung neoplasms’, ‘lung tumor’, ‘lung tumors’, ‘lung
tumour’, ‘lung tumours’, ‘lung adenocarcinoma’, ‘lung squamous’,
‘NSCLC’, ‘non-small cell lung cancer’, ‘non small cell lung
cancer’, ‘non-small cell lung carcinoma’, ‘non small cell
lung carcinoma’, ‘SCLC’, ‘small cell lung cancer’, ‘small cell lung
carcinoma’, ‘cyclooxygenase’, ‘cyclooxygenase-2’, ‘COX-2’. The
bibliographies reported in all the identified studies were used to
complete this search, which ended on December 2005.
Methodological assessment
To assess the methodology, each study report was read indepen-
dently by 10 investigators. The participation of many readers was a
guarantee for the correct interpretation of the articles. The
methodological evaluation was scored according to the European
Lung Cancer Working Party (ELCWP) scale previously published
(Steels et al, 2001) and applied in other meta-analyses (Delmotte
et al, 2002; Meert et al, 2002a,b, 2003; Martin et al, 2003, 2004;
Mascaux et al, 2005a). Each item was assessed using an ordinal
scale (possible values: 2, 1, 0). A consensus was reached in regular
meetings where at least two-thirds of the investigators needed to be
present. As the assessed items were objective ones, a consensus
was always obtained.
The overall score evaluated several dimensions of the metho-
dology, grouped in four main categories: the scientific design, the
description of laboratory methods used to identify COX-2
expression, the generalisability of the results and the analysis of
the study data. Each category had a maximum score of 100 points,
with a maximal theoretical score of 400 points. When an item was
not applicable to a study, its value was not taken into account in
the total of the concerned category. The final scores were expressed
as percentages, ranging from 0 to 100%, higher values reflecting
better methodological quality. Studies included in the systematic
review were called ‘eligible’, those providing sufficient data for the
meta-analysis ‘evaluable’. To be eligible, studies had to provide
univariate survival analysis according to COX-2.
Statistical methods
A study was considered significant if the P-value for the statistical
test, comparing survival distributions between the groups with
and without COX-2 increase, was o0.05. A study was called
respectively, ‘positive’ or ‘negative’ when COX-2 increase was
identified as a significant favourable or unfavourable prognostic
factor for survival. These studies were further called ‘significant’
ones. Finally, a study was called ‘not significant’ if no statistically
significant difference between the two groups was detected.
The association between two continuous variables was measured
by the Spearman rank correlation coefficient. Non-parametric tests
were used to compare the distribution of the quality scores
according to the value of a discrete variable (Mann–Whitney tests
for dichotomic variables and Kruskal–Wallis tests for multiple
classes variables).
For the quantitative aggregation of the survival results, we
measured the impact of COX-2 increase on survival by hazard ratio
(HR) between the two survival distributions. For each trial, this HR
was estimated by a method depending on the data provided in the
publication. The most accurate method consisted of extracting the
estimated HR and its standard error (s.e.) from the reported results
using two of the following parameters: the HR and its confidence
interval (CI) or the O E statistic (difference between numbers of
observed and expected events), and the log-rank statistic or its
P-value. If these data were not available, the total number of
events, the number of patients at risk in each group and the log-
rank statistic or its P-value were used to allow for an approxima-
tion of the HR estimate. Finally, if the only exploitable data were in
the form of graphical representations of the survival distributions,
survival rates at some specified times were extracted in order to
reconstruct the HR estimate and its variance, with the assumption
that the rate of patients censored was constant during the study
follow-up (Parmar et al, 1998). If this last method was used, three
independent persons read the curves to reduce inaccuracy in the
extracted survival rates. The individual HR estimates were
combined into an overall HR using Peto’s method (Yusuf et al,
1985), which consisted of using a fixed-effect model assuming
homogeneity of the individual true HRs. This assumption was
tested by performing w
2 tests for heterogeneity. If the assumption
of homogeneity had to be rejected, we used a random-effect model
as a second analysis. By convention, an observed HRo1 implied a
better survival for the group with COX-2 increase. This impact of
COX-2 on survival was considered statistically significant if the
95% CI for the overall HR did not overlap 1.
When data about global survival of the entire patients’
population were available, survival was analysed globally. If
authors only reported the results separately for different sub-
groups, those results corresponding to different cohorts of patients
were treated separately in the meta-analysis.
RESULTS
Study selection and characteristics
Fourteen publications, published between 1999 and 2005, were
eligible for the systematic review (Achiwa et al, 1999; Hosomi et al,
2000; Khuri et al, 2001; Brabender et al, 2002; Kim et al, 2003;
Ab’ Saber et al, 2004; Araki et al, 2004; Lu et al, 2004; Yamaguchi
et al, 2004; Brattstrom et al, 2005; Laga et al, 2005; Marrogi et al,
2005; Richardson et al, 2005; Yuan et al, 2005). These publications
concerned different cohorts of patients. The total number of
included patients was 1543, ranging from 53 to 259 patients per
study (median: 92). The main characteristics of the 14 eligible
publications are reported in Table 1. Nine were dealing with all
types of NSCLC, four with ADC and one with large-cell carcinoma.
Seven studies only concerned locoregional diseases (two studies
concerned stages I–IIIA and four, stages I–IIIB), four only stage I
disease and four all stages (I–IV).
Ten studies evaluated COX-2 expression by immunohisto-
chemistry (IHC), two studies assessed COX-2 mRNA overexpres-
sion by reverse transcription–polymerase chain reaction
(RT–PCR) in real time and the last two studies determined
COX-2 gene amplification by in situ hybridisation.
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sAmong the 14 studies eligible for the systematic review, four
(Hosomi et al, 2000; Ab’ Saber et al, 2004; Brattstrom et al, 2005;
Marrogi et al, 2005) were inevaluable for the meta-analysis owing
to a lack of data in the publication, not allowing to calculate the
individual HR and its variance.
Study results report
Six of the 14 studies identified COX-2 overexpression as a poor
prognostic factor for survival (with five evaluable for the meta-
analysis) whereas one reported that it was a good prognostic factor
(evaluable for the meta-analysis). The seven other studies showed
no statistically significant impact of COX-2 overexpression on
survival (four evaluable for meta-analysis).
Overall, in NSCLC, the rates of COX-2 protein overexpression
(detected by IHC), COX-2 mRNA expression (RT–PCR) and
COX-2 gene amplification (detected by in situ hybridisation)
were respectively, 62.4% (number of evaluable tumours n¼833,
51.7% (n¼149) and 59.8% (n¼254). For ADC, IHC and ISH
assessments reported were respectively, 69% of COX-2-positive
tumours (n¼368) and 41.2% (n¼34). The rates of positive
tumours by IHC, RT–PCR and in situ hybridisation in stage I
NSCLC were, respectively, 65% (n¼240), 50% (n¼60) and 59.8%
(n¼254).
Quality assessment
The overall quality score ranged from 36.3 to 66.0% with a median
of 51.5%. No statistically significant quality difference was shown
between significant and non-significant studies for the global score
(median: 55.4 vs 48.9%, P¼0.06). There was also no statistically
significant difference between evaluable and non-evaluable studies
for meta-analysis in terms of global scores (51.5 vs 53.4%,
P¼0.78).
We performed the same analysis of the scores for the 10 studies
evaluable for meta-analysis. Their overall quality score ranged
between 41.8 and 66%, with a median of 51.5%. As previously
observed among eligible publications, there was no statistically
significant difference between significant and non-significant
studies evaluable for the meta-analysis according to the global
score (median of 54.6 vs 48.4%, P¼0.09).
Meta-analysis
The meta-analysis was performed on 10 studies (1236 patients)
dealing with NSCLC, and were shown to have similar methodo-
logical scores.
The individual HRs of the 10 evaluable studies were calculated
by one of the three methods reported in the Materials and Methods
section according to available data. One study reported the data
needed to directly calculate the estimated HR (95% CI). In two
trials, HR was approximated by the total number of events and the
log-rank statistic. For the seven remaining studies, HR had to be
extrapolated from the graphical representation of the survival
distributions.
The results of the meta-analysis are reported in Table 2 and in
Figure 3. Overall, COX-2 overexpression was not associated with a
significant impact on survival. As the test for heterogeneity was
highly significant (Po0.001), we also applied a random-effect
model in calculating the HR, which was 1.39 (95% CI: 0.97–1.99)
(Figure 1).
Regarding subgroup analyses (Figure 3), we had the adequate
data to aggregate the studies dealing with stage I, with ADC and
according to the technique used to detect Cox-2. We first
performed an interaction test to assess whether there might be a
differential effect of COX-2 according to stage, histology or the
technique. We found one significant interaction between COX-2
and stage (Po0.01). When we aggregated the six studies (Achiwa
et al, 1999; Khuri et al, 2001; Araki et al, 2004; Lu et al, 2004;
Richardson et al, 2005; Yuan et al, 2005) giving separate results
about stage I NSCLC, the combined HR was statistically significant
by using the random-effect model: HR 1.64, 95% CI (1.21–2.24) as
there was indeed a significant heterogeneity (P¼0.04) (Figure 2).
We did not observe a statistically significant effect of COX-2 on
survival in ADC (five evaluable studies) (Achiwa et al, 1999; Araki
et al, 2004; Yamaguchi et al, 2004; Richardson et al, 2005; Yuan
et al, 2005) with HR 1.35 (95% CI 0.62–2.95) (random effect;
test of heterogeneity Po0.001). We also found one significant
interaction between COX-2 and the technique used for its
detection (P¼0.003). The test of heterogeneity was significant
for the IHC studies (P¼0.00001), but neither for RT–PCR studies
(P¼0.1), nor, for ISH studies (P¼0.18). As the number of studies
in the subgroups was small, we only report the HR estimated by
the random effect because of a lack of power of the test of
Table 1 Main characteristics and results of the eligible studies
First author Year Histology Stage N pts
Laboratory
method
Antibody for
IHC, dilution
Definition of
Cox-2
positivity HR estimation Evaluable
Survival
results
Ab’ Saber 2004 LC I–IIIB 61 IHC Dako, 50 Score 1 No data No Negative
Achiwa 1999 ADC I–IIIB 130 IHC IBL, 25 I4ref Surv. curves Yes NS
Araki 2004 ADC I 71 IHC Cayman, 500 410% Log rank Yes Negative
Brabender 2002 NSCLC I–IIIA 89 RT-PCR Ratio ref. Surv. curves Yes Negative
Brattstrom 2004 NSCLC I–IV 53 IHC SantaCruz, 1000 467% + I No data No NS
Hosomi 2000 ADC I–IIIB 87 IHC IBL, 50 410% No data No NS
Khuri 2001 NSCLC I 160 ISH 1% Surv. curves Yes NS
Kim 2003 NSCLC I–IIIA 84 IHC Cayman, 100 Score 2 Surv. curves Yes Negative
Laga 2005 NSCLC I–IV 259 IHC Cayman, 150 Score 3 Surv. curves Yes NS
Lu 2004 NSCLC I 94 ISH 1% HR Yes Negative
Marrogi 2000 NSCLC I–IV 106 IHC SantaCruz, 100 Score 4 No data No NS
Richardson 2005 NSCLC I–IIIA 172 IHC SantaCruz, 400 450%* Surv. curves Yes NS
Yamaguchi 2004 ADC I–IIIB 117 IHC Transduc.,100 Score 5 Log rank Yes Positive
Yuan 2005 NSCLC I–IV 60 RT-PCR Ratio ref. Surv. curves Yes Negative
Abbreviations:ADC, adenocarcinoma; HR, hazard ratio; IBL, Immuno-biological laboratory; IHC, immunohistochemistry; ISH, in situ hybridisation; N pts, number of patients;
NSCLC, non-small–cell lung cancer; ref, reference; RT–PCR, reverse transcriptase–polymerase chain reaction; surv. curves, survival curves; LC, large cell; NS: non significative;
Transduc: Transduction; score 1: score from 0 to 8 without any explanation, positive X2, I: intensity; score 2, 3, 4, 5: different scores with combination of percentage of positives
cells and intensity, *: 450%: thresehold¼median of positivity for COX-2, which was 50%. HR estimation: description of the methods used to estimate the individual HR
according to the three different methods described in the statistics methodology (see statistical methods).
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sheterogeneity. The HRs were the following: for the six studies with
IHC (833 patients) 1.06 (95% CI 0.64–1.77), for the two RT–PCR
studies (149 patients) 3.15 (1.08–9.21), for the two ISH studies
(254 patients) 1.40 (0.94–2.07) and for RT–PCR and ISH studies
together (403 patients) 1.31 (0.97–1.76).
DISCUSSION
The present systematic review of the literature about the impact of
COX-2 overexpression on survival in lung cancer found a slight
role of COX-2 on overall survival in NSCLC, without not reaching
statistical significance. When the analysis was restricted to stage I
NSCLC, we observed a statistically significant detrimental effect of
COX-2 on survival, suggesting that this prognostic factor could
be of importance in early-stage NSCLC. In subgroup analysis
according to the different techniques used to detect COX-2, results
were only significant with RT–PCR.
The search for a potential prognostic role of COX-2 in survival
for patients with lung cancer is based on its frequent over-
expression in NSCLC and also on its potential interference with
most pathways implicated in lung carcinogenesis. The role of
COX-2 in oncogenesis has widely been studied by in vitro
experiments and by in vivo analyses based on animal models. In
lung cancer, COX-2 overexpression is associated with micro-
vascular angiogenesis (Masferrer et al, 2000) and resistance to
apoptosis (Liu et al, 1998; Hida et al, 2000). Cyclooxygenase-2
overexpression also decreases host immunity (Huang et al, 1998)
and alters cell adhesion with enhancement of invasion and
metastasis (Tsujii et al, 1997). Despite all these experimental
observations, our meta-analysis failed to demonstrate in univariate
analysis a statistically significant impact of COX-2 expression as a
prognostic factor for overall survival in patients with NSCLC. In
subgroup analysis, we observed a significant effect in stage I
NSCLC. Cyclooxygenase-2 overexpression might modify the
prognosis of early-stage NSCLC: early lung cancer overexpressing
COX-2 would be more aggressive and would have a worse
prognosis than those without COX-2 abnormality. These data
could be helpful to determine among stage I diseases those who
Table 2 Meta-analysis: HR value in NSCLC subgroups according to histology, stage
Nb Patients v
2 heterogeneity test Random effects HR (95% CI)
Overall 10 1236 P¼0.000001 1.39 (0.97–1.99)
Stage I disease 6 554 P¼0.04 1.64 (1.21–2.24)
Adenocarcinoma 5 402 P¼0.000001 1.35 (0.62–2.95)
IHC 6 833 P¼0.00001 1.06 (0.64–1.77)
RT–PCR 2 149 P¼0.1 3.15 (1.08–9.21)
ISH 2 254 P¼0.18 1.40 (0.94–2.07)
RT–PCR + ISH 4 403 P¼0.03 1.31 (0.97–1.76)
Abbreviations: HR, hazard ratio; IHC, immunohistochemistry; ISH, in situ hybridisation; Nb, number of studies; RT–PCR, reverse transcriptase–polymerase chain reaction.
Statistically significant results are in bold.
Achiwa et al (1999)
Araki et al (2004)
Brabender et al 2004
Khuri et al 2001
Kim et al 2003
Yuan et al 2005
Richardson et al 2005
Lu et al 2004
Laga et al 2005
Yamagushi et al 2004
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Figure 1 Meta-analysis of the 10 evaluable studies assessing COX-2 in
NSCLC. Hazard ratio and 95% CI of survival in studies evaluating COX-2
status in NSCLC. HR41 implies a survival disadvantage for the group with
COX-2 expression. The square size is proportional to the number of
patients included in the study. The centre of the lozenge gives the
combined HR of the meta-analysis and its extremities give the 95% CI.
HR¼1.39; CI 95% 0.97–1.99. Total number of patients: 1236.
Achiwa et al (1999)
Araki et al (2004)
Khuri et al 2001
Yuan et al 2005
Richardson et al 2005
Lu et al 2004
0.0 2.0 4.0 6.0 8.0
Figure 2 Meta-analysis of the six evaluable studies assessing COX-2 in
stage I NSCLC. Hazard ratio and 95% CI of survival in studies evaluating
COX-2 status in NSCLC. HR41 implies a survival disadvantage for the
group with COX-2 expression. The square size is proportional to the
number of patients included in the study. The centre of the lozenge gives
the combined HR of the meta-analysis and its extremities give the 95% CI.
Hazard ratio¼1.64; CI 95% 1.21–2.24. Total number of patients: 554.
Overall
Stage 1
Adenocarcinoma
IHC
PCR
ISH
PCR + ISH
0.0 1.0 2.0 3.0 4.0
Figure 3 Overall and subgroup analyses. Hazard ratio and 95% CI of
survival in studies evaluating COX-2 status in NSCLC. HR41 implies a
survival disadvantage for the group with COX-2 expression. The square
size is proportional to the number of patients included in the study and its
extremities gives the 95% CI. The Figure 3 shows that there is a trend for a
pejorative role of COX-2 as a prognostic survival in NSCLC and that the
results become significant (CI not crossing 1) for the subgroups of stage 1
and of RT–PCR.
Meta-analysis: prognostic role of COX-2 in lung cancer
C Mascaux et al
142
British Journal of Cancer (2006) 95(2), 139–145 & 2006 Cancer Research UK
C
l
i
n
i
c
a
l
S
t
u
d
i
e
scould benefit from a more aggressive treatment. But the present
results concerning the prognostic role of COX-2 in stage I NSCLC
still need to be confirmed by adequately designed prospective
studies with multivariate analysis before a potential clinical
application.
It should be noted that COX-2 appears early in oncogenesis for
SQCC (Mascaux et al, 2005b) as well as for ADC (Hida et al, 1998;
Wolff et al, 1998; Hosomi et al, 2000; Hasturk et al, 2002). In a
previous study (Mascaux et al, 2005b), we observed that COX-2
expression increases in bronchial preneoplastic lesions at the stage
of severe dysplasia and particularly in clones of cells showing
atypia: this suggests an active role of COX-2 in bronchial epithelial
cells transformation to malignancy. These data could partially
explain the prognostic role of COX-2 at stage I, its impact being
lost at later steps because of the potential interaction with many
factors.
Our analysis had to deal with heterogeneity problems. There was
a highly significant heterogeneity among the 10 evaluable studies
included in the meta-analysis. This could be explained by the type
of patients and the disease characteristics, or by the diversity in the
techniques used to identify alteration of COX-2 status. Only six
evaluable studies used IHC, two ISH and two RT–PCR. The results
of subgroup analysis according to the technique used to detect
COX-2 support this hypothesis. Results for the six IHC studies
were not significant and a high heterogeneity was detected between
the studies (P¼0.003). This heterogeneity could be explained by
the fact that the technique of IHC is not comparable among the six
studies. The primary antibodies were different and so was the
revelation protocols, and different levels of positivity (0, 10, 50%,
different scores combining intensity and percentage, intensity
only) were used. As another example, when ISH and RT–PCR (two
different techniques assessing RNA) studies were aggregated
together, the heterogeneity increased (P¼0.03) as compared with
ISH alone (P¼0.18) or RT–PCR alone (P¼0.1), and with only a
few studies, the results were statistically significant for the RT–
PCR subgroup, which is the most standardised technique. It is
thus very important to use a well-defined and well-standardised
technique to be reproducible for the evaluation of biological
markers. Particularly, the protocol of IHC should be the same
between different laboratories (same antibody, same revelation
protocol (pH and compounds of the solutions, heating method etc)
and same criteria of evaluation for the positivity of the marker) so
that the results could be compared and eventually, aggregated.
Some other biases could be due to the methodology used to
perform our systematic review. We performed a methodological
assessment of the studies to avoid some selection biases (more
detailed reports of significant trials), as we performed in prior
studies about biological prognostic factors in lung cancer (Steels
et al, 2001). The absence of a detectable difference in quality score
between significant and non-significant studies, and between
evaluable and non-evaluable studies, encourages us to perform a
quantitative aggregation (meta-analysis) of the results of the
individual trials. However, in the present review, numbers of
studies are small, preventing us to analyse any potential difference
between significant and non-significant, or evaluable and non-
evaluable studies. However, this approach does not prevent all
potential biases. Publication bias, choice of language, selection of
fully published studies only, method of extrapolation of HR,
validity of a meta-analysis based on systematic review of the
literature as compared with those based on individual data were
already discussed in our previous papers (Steels et al, 2001).
Some eligible trials had to be excluded from the meta-analysis
because they did not provide sufficient data on survival. Among
the four excluded studies, only one (25%) was statistically
significant, whereas a higher proportion of the studies evaluable
for the meta-analysis were significant (60%). It is known that
negative studies are less frequently published or, if they are, with
less detailed results, making them less assessable. The methodo-
logical quality of trials, according to the global score, was not
significantly different between evaluable and non-evaluable studies
for the quantitative aggregation of individual survival results.
Nevertheless, such an approach does not fully protect a potential
bias owing to the impossibility taking into account all the studies
with negative or non-significant results.
Our meta-analysis is based on published data collected by a
systematic review of the literature and can only be performed by
univariate analysis. This is a limit to this type of work, which
appears thus as a preliminary step before performing multivariate
studies. Many interesting data arise from multivariate analyses
and particularly from proteomic and genomic wide screen
analysis, which is probably the way of the future. But if
microarrays is an interesting technique providing very meaningful
data, it should be kept in mind that it remains a research screening
technique and that it could not be applied in routine because of the
high price.
It should also be noted that COX-2 expression increases in
patient treated by taxanes (Subbaramaiah et al, 2003; Altorki et al,
2005), providing an argument to treat patients with lung cancer
by an association of taxanes and anti-COX-2 drugs. The studies
analysing COX-2 expression after a specific treatment were not
included in this meta-analysis because treated and untreated
tumours do not have the same biological behaviour and
should not be aggregated together. This topic, COX-2 expression
in pretreated lung tumours, should be the topic of another
systematic review.
In conclusion, when all stages and histologies are considered,
there is a trend for COX-2 overexpression as a prognostic factor
for survival in patients with NSCLC, but there is a high
heterogeneity between the studies and these results are not
statistically significant. Interestingly, our meta-analysis showed
with more evidence that COX-2 has a detrimental effect on survival
in stage I NSCLC. This prognostic role of COX-2 at earliest stage of
NSCLC could be of clinical interest in the selection of the patients
eligible for induction or adjuvant chemotherapy. Hazard ratio was
also significant for the studies using RT–PCR and not for those
using IHC, suggesting that a better standardisation of the
technique to define and to detect COX-2 positivity is required to
the generalisability of the results. Our results need to be confirmed
by an adequately designed prospective study and the exact role of
COX-2 overexpression needs to be determined by an appropriate
multivariate analysis taking into account the classical well-defined
(at the moment of the study) prognostic factors for lung cancer
such as PS, stage, age, sex, weight loss.
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